- Report
- October 2024
- 195 Pages
Global
From €3226EUR$3,545USD£2,766GBP
€3585EUR$3,939USD£3,073GBP
- Report
- October 2024
- 181 Pages
Global
From €3226EUR$3,545USD£2,766GBP
€3585EUR$3,939USD£3,073GBP
- Report
- March 2025
- 175 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3413EUR$3,750USD£2,926GBP
- Report
- January 2019
- 144 Pages
Global
From €1251EUR$1,375USD£1,073GBP
€2503EUR$2,750USD£2,146GBP
- Report
- August 2022
- 117 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €1138EUR$1,250USD£975GBP
- Report
- October 2023
- 84 Pages
Canada
From €3185EUR$3,500USD£2,731GBP
- Report
- October 2023
- 89 Pages
Egypt
From €3185EUR$3,500USD£2,731GBP
- Report
- August 2023
- 75 Pages
Israel
From €3185EUR$3,500USD£2,731GBP
- Report
- January 2022
- 115 Pages
Global
From €4323EUR$4,750USD£3,706GBP
- Report
- October 2023
- 74 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Book
- March 2015
- 512 Pages
The Renin Inhibitor market is a subset of the Cardiovascular Drugs market. Renin Inhibitors are a class of drugs used to treat hypertension, or high blood pressure. These drugs work by blocking the action of the enzyme renin, which is responsible for the production of angiotensin II, a hormone that causes blood vessels to constrict. By blocking the action of renin, Renin Inhibitors can help reduce blood pressure and improve cardiovascular health.
Renin Inhibitors are typically prescribed in combination with other drugs, such as diuretics and beta blockers, to help reduce blood pressure. They are also used to treat other conditions, such as heart failure and chronic kidney disease.
Some of the companies in the Renin Inhibitor market include Novartis, AstraZeneca, Merck, and Daiichi Sankyo. Show Less Read more
